Research Article

An Intelligent Clinical Decision Support System for Patient-Specific Predictions to Improve Cervical Intraepithelial Neoplasia Detection

Table 20

Performance of several type “AND” combinations between more than two tests in detecting CIN2+.

Combinations of medical testsCytology cutoffSensitivity (%)Specificity (%)PPV (%)NPV (%)Youden’s index

Pap test and HPV DNA and NASBAASCUS+74.591.571.092.80.66
Pap test and HPV DNA and NASBALSIL+70.292.973.491.80.63
Pap test and HPV DNA and NASBA HSIL+57.898.189.489.30.56
Pap test and HPV DNA and FLOWASCUS+ 86.387.766.295.80.74
Pap test and HPV DNA and FLOW LSIL+80.788.967.094.30.70
Pap test and HPV DNA and FLOWHSIL+63.497.487.290.50.61
Pap test and HPV DNA and p16ASCUS+55.394.874.888.40.50
Pap test and HPV DNA and p16LSIL+53.495.074.888.00.48
Pap test and HPV DNA and p16HSIL+46.698.690.486.90.45
Pap test and HPV DNA and NASBA and FLOWASCUS+71.493.174.292.10.65
Pap test and HPV DNA and NASBA and FLOW LSIL+67.194.075.591.10.61
Pap test and HPV DNA and NASBA and FLOWHSIL+55.398.490.888.80.54
Pap test and HPV DNA and NASBA and FLOW and p16ASCUS+44.798.891.186.50.44
Pap test and HPV DNA and NASBA and FLOW and p16LSIL+43.598.890.986.30.42
Pap test and HPV DNA and NASBA and FLOW and p16HSIL+38.599.595.485.30.38
HPV DNA and NASBA and FLOW72.093.174.492.30.65
HPV DNA and NASBA and p1646.697.684.386.80.44
HPV DNA and NASBA and FLOW and p1645.398.891.386.70.44
NASBA and FLOW and p1647.298.891.687.10.46

Statistical measures have been calculated using all cases of the dataset (Table 1). Histology endpoint is CIN2+ for all cases. Definition of positivity of each medical test is presented in Table 15. CIN2+: cervical intraepithelial neoplasia grade 2 or worse, HR-HPV: high-risk human papillomavirus, NASBA: nucleic acid sequence based amplification for the identification of E6/E7 mRNA of the HPV types 16, 18, 31, 33, and 45, FLOW: flow cytometric E6/E7 HPV mRNA assay, PPV: positive predictive value, and NPV: negative predictive value.